| Code | CSB-MP023974HU1 |
| Abbreviation | Recombinant Human Tnfrsf17 protein, partial (Active) |
| MSDS | |
| Size | $9.9 |
| Promotion | |
| Order now | |
| Image |
|
| Have Questions? | Leave a Message or Start an on-line Chat |
Less than 1.0 EU/ug as determined by LAL method.
BCMA (TNFRSF17/CD269) is a critical therapeutic target in multiple myeloma, and this recombinant construct covers the extracellular ligand-binding domain (residues 1–54) fused to a C-terminal hFc1 tag, providing the minimal receptor architecture necessary for ligand and antibody interaction studies. Functional ELISA validation demonstrates that immobilized BCMA at 2 μg/ml binds anti-BCMA recombinant antibody with an EC50 of 1.912–2.488 ng/ml, confirming conformational integrity suitable for therapeutic antibody epitope mapping, blocking antibody screening, and affinity characterization by SPR or BLI. Mammalian cell expression ensures native-like glycosylation and proper disulfide bond formation within this cysteine-rich domain, which supports use in receptor-ligand interaction assays and as a positive control in binding studies for biologic inhibitor discovery. Purity exceeding 90% by SDS-PAGE combined with endotoxin levels below 1.0 EU/μg satisfies the criteria typical for cell-based functional assays in immuno-oncology research.
Applications : ELISA standard and its raw materials
Review: We coated TNFRSF17 on the plate and performed a functional ELISA experiment with the ligand human TNFSF13B-Biotinylated, and the EC50 was 0.3101-0.5710 ng/ml, showing good binding activity. Since it will be used as standard in my subsequent experiment for activity testing, which requires high protein purity, low endotoxin, and good biological activity, CUSABIO\'s product has just met our needs perfectly, and the subsequent experiments have progressed smoothly!
By Anonymous